Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.

K. Murugan Biography and Net Worth

SVP of Atara Biotherapeutics

K. Amar Murugan is the Senior Vice President, General Counsel at Atara Biotherapeutics Inc.

What is K. Amar Murugan's net worth?: The estimated net worth of K. Amar Murugan is at least $161,888.51 as of August 16th, 2023. Mr. Murugan owns 265,391 shares of Atara Biotherapeutics stock worth more than $161,889 as of May 19th. This net worth approximation does not reflect any other investments that Mr. Murugan may own. Additionally, Mr. Murugan receives a salary of $618,520.00 as SVP at Atara Biotherapeutics. Learn More about K. Amar Murugan's net worth.
How old is K. Amar Murugan?: Mr. Murugan is currently 48 years old. There are 3 older executives and no younger executives at Atara Biotherapeutics. The oldest executive at Atara Biotherapeutics is Dr. Pascal Touchon D.V.M., President, CEO & Director, who is 61 years old. Learn More on K. Amar Murugan's age.
What is K. Amar Murugan's salary?: As the SVP of Atara Biotherapeutics, Inc., Mr. Murugan earns $618,520.00 per year. The highest earning executive at Atara Biotherapeutics is Dr. Pascal Touchon D.V.M., President, CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on K. Amar Murugan's salary.
How do I contact K. Amar Murugan?: The corporate mailing address for Mr. Murugan and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (805) 623-4211 and via email at [email protected]. Learn More on K. Amar Murugan's contact information.
Has K. Amar Murugan been buying or selling shares of Atara Biotherapeutics?: K. Amar Murugan has not been actively trading shares of Atara Biotherapeutics in the last ninety days. Most recently, Amar Murugan sold 8,672 shares of the business's stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $1.65, for a transaction totalling $14,308.80. Following the completion of the sale, the executive vice president now directly owns 265,391 shares of the company's stock, valued at $437,895.15. Learn More on K. Amar Murugan's trading history.
Who are Atara Biotherapeutics' active insiders?: Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.
Are insiders buying or selling shares of Atara Biotherapeutics?: During the last year, Atara Biotherapeutics insiders bought shares 2 times. They purchased a total of 279,020 shares worth more than $64,384.40. During the last year, insiders at the biotechnology company sold shares 9 times. They sold a total of 138,728 shares worth more than $144,004.43. The most recent insider tranaction occured on March, 4th when CEO Pascal Touchon sold 24,844 shares worth more than $17,887.68. Insiders at Atara Biotherapeutics own 4.5% of the company. Learn More about insider trades at Atara Biotherapeutics.
Information on this page was last updated on 3/4/2024.

K. Amar Murugan Insider Trading History at Atara Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2023	Sell	8,672	$1.65	$14,308.80	265,391
5/16/2023	Sell	8,389	$2.04	$17,113.56	270,945
3/2/2023	Sell	4,221	$3.63	$15,322.23	279,334
11/16/2022	Sell	3,612	$4.49	$16,217.88	127,586
8/16/2022	Sell	3,430	$5.03	$17,252.90	131,198
5/17/2022	Sell	3,223	$5.32	$17,146.36	133,735
11/16/2021	Sell	2,124	$17.12	$36,362.88
8/17/2021	Sell	2,080	$12.53	$26,062.40	89,664

K. Amar Murugan Buying and Selling Activity at Atara Biotherapeutics

Atara Biotherapeutics Company Overview

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $0.61

$0.59

$0.63

50 Day Range

MA: $0.67

$0.53

$0.78

2 Week Range

Now: $0.61

$0.20

$2.54

Volume

1,824,800 shs

Average Volume

2,459,560 shs

Market Capitalization

$73.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

The most important AI company you've never heard of

From Manward Press | Ad

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth

K. Murugan Biography and Net Worth

What is K. Amar Murugan's net worth?

How old is K. Amar Murugan?

What is K. Amar Murugan's salary?

How do I contact K. Amar Murugan?

Has K. Amar Murugan been buying or selling shares of Atara Biotherapeutics?

Who are Atara Biotherapeutics' active insiders?

Are insiders buying or selling shares of Atara Biotherapeutics?